Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

  • STATUS
    Recruiting
  • participants needed
    120
  • sponsor
    Royal Perth Hospital
Send
Updated on 16 February 2024
See if I qualify
body mass index
hypertension
amlodipine
ace inhibitor
amlodipine 5 mg
moxonidine

Summary

This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.

Description

This is a randomised, double-blind, cross-over study. Participants will be randomly assigned to receive either moxonidine 0.4mg daily or amlodipine 5mg and will later receive the alternate treatment.

Comprehensive testing will occur after each 12 week treatment phase and will include assessment of muscle sympathetic nerve activity, gut microbiome analysis and metabolic markers.

Details
Condition Vascular Diseases, Vascular Diseases, Hypertension, Obesity, Obesity
Age 25years - 65years
Treatment Moxonidine 0.4 MG, Amlodipine 5mg
Clinical Study IdentifierNCT04474899
SponsorRoyal Perth Hospital
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age: 25 -65 years
(Body Mass Index) BMI30kg/m2
Currently weight stable (+/- 3% in previous 6-12 months and not on any specific exercise or dietary program)
Elevated clinic systolic (Blood Pressure) BP 135 or diastolic BP 85mmHg
on ACE inhibitor for at least 6 weeks prior to baseline assessment

Exclusion Criteria

Grade 2-3 hypertension (systolic office BP >160, diastolic office BP >100 mmHg)
Secondary causes of hypertension
CKD (Chronic kidney disease) stage 4-5 {(estimated glomerular filtration) eGFR<30ml/min}
Heart failure NYHA (New York Heart Association) class II-IV
Recent CV (cardiovascular) event (acute myocardial infarction, acute coronary syndrome, stroke or transient ischaemic attack within the previous six months) unstable psychiatric condition
medication such as corticosteroids, several antidepressants and antipsychotics
Female participants of childbearing potential must have a negative pregnancy test prior to treatment
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

body mass index
hypertension
amlodipine
ace inhibitor
amlodipine 5 mg
moxonidine

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.